KPMA suggested special tax privileges for R&D to extend.

The Ministry of Finance and Economy earlier disclosed the revised draft of the special tax privilege act in advance, which restricted the pharmaceutical industry for the R&D investment and the new drug development by eliminating the special tax privileges given to the pharmaceutical technology transfer incomes. The KPMA therefore suggested to the MOFE for the maintenance of its tax privileges. ...